Group 1: Bristol Myers Squibb - Bristol Myers Squibb is a leading drugmaker with a strong presence in oncology and a vast portfolio of products, with 10 products generating over $1 billion in sales last year [5] - The company faces patent cliffs for its best-selling drugs, Eliquis and Opdivo, but has a growth portfolio of newer therapies to replace older ones [6] - A new subcutaneous formulation of Opdivo will help maintain its franchise, and newer products are expected to significantly impact revenue once Eliquis loses patent exclusivity [7] - Bristol Myers Squibb offers an attractive dividend with a forward yield of 4% and has increased its dividend payout by 65.8% over the past decade [8] Group 2: Medtronic - Medtronic is a leader in medical devices, with a portfolio that includes innovative products like pulsed field ablation for treating heart problems [9] - The company consistently launches new products and has reliable revenue and earnings growth, with the Hugo system for robotic-assisted surgery expected to be a significant long-term growth driver [10]
2 Top Healthcare Dividend Stocks to Buy and Hold Forever